BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors

the Israel Lung Cancer Group

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors'. Together they form a unique fingerprint.

Medicine & Life Sciences